大剂量美法仑治疗显著增加多发性骨髓瘤复发时的突变负荷
该研究基于IFM 2009试验,对68例多发性骨髓瘤患者诊断与复发配对样本行深度全基因组测序,其中43例接受RVD治疗、25例接受RVD+大剂量美法仑(HDM)。两组诊断时突变数相似(7137 vs 7230,P=.67),但HDM组复发时突变数显著更多(9242 vs 13383,P=.005),且新获得突变与DNA损伤和双链断裂相关、主要位于转录链。
要点
- HDM组复发时突变数显著多于RVD组(9242 vs 13383,P=.005),诊断时两组相似(7137 vs 7230,P=.67)。
- 拷贝数改变或结构变异频率未见变化,新获得突变主要位于转录链并与DNA损伤和双链断裂相关。
- HDM组全部患者均出现克隆选择,RVD组呈静态进展;HDM组亚克隆突变比例显著更高。
核心结论
- 研究识别出与大剂量美法仑相关的基因组改变增加,为进一步理解克隆复杂性提供了依据。
研究设计与样本
- 基于IFM 2009研究,对68例多发性骨髓瘤患者诊断与复发配对样本行深度全基因组测序,其中43例接受RVD治疗、25例接受RVD+HDM治疗。
主要发现
- 诊断时两组突变数相似(7137 vs 7230,P=.67),复发时HDM组显著多于RVD组(9242 vs 13383,P=.005)。
- 拷贝数改变或结构变异频率未见变化。
- 新获得突变通常与DNA损伤和双链断裂相关,且主要位于转录链。
- 机器学习模型利用该独特模式预测接受HDM的患者,具有高敏感性、特异性和阳性预测值。
- 克隆演化分析显示HDM组全部患者均出现克隆选择,而RVD组呈静态进展;HDM组亚克隆突变比例显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse in the IFM 2009 study. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD + HDM. Although the number of mutations was similar at diagnosis in both groups (7137 vs 7230; P = .67), the HDM group had significantly more mutations at relapse (9242 vs 13 383, P = .005). No change in the frequency of copy number alterations or structural variants was observed. The newly acquired mutations were typically associated with DNA damage and double-stranded breaks and were predominantly on the transcribed strand. A machine learning model, using this unique pattern, predicted patients who would receive HDM with high sensitivity, specificity, and positive prediction value. Clonal evolution analysis showed that all patients treated with HDM had clonal selection, whereas a static progression was observed with RVD. A significantly higher percentage of mutations were subclonal in the HDM cohort. Intriguingly, patients treated with HDM who achieved complete remission (CR) had significantly more mutations at relapse yet had similar survival rates as those treated with RVD who achieved CR. This similarity could have been due to HDM relapse samples having significantly more neoantigens. Overall, our study identifies increased genomic changes associated with HDM and provides rationale to further understand clonal complexity.
引用
- Samur MK, Roncador M, Aktas Samur A, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023. PMID: 36603186. doi:10.1182/blood.2022017094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。